EGFR and non-small cell lung carcinoma: For the 85–90% of patients with NSCLC who do not have mutations associated with drug sensitivity (i.e., in genes targeted by EGFR kinase inhibitors), platinum-based chemotherapy remains the standard first-line chemotherapy [4].